Savient Pharmaceuticals (SVNT -9%) takes a hit after its Q4 beat expectations on a per share...


Savient Pharmaceuticals (SVNT -9%) takes a hit after its Q4 beat expectations on a per share basis, but came up far short on revenue as net sales of Krystexxa posted a marginal 3% increase over Q3. Bottom line margins were also impacted by a cost of goods charge to Krystexxa inventory that the company doesn't believe will be sold prior to expiration.

From other sites
Comments (1)
  • bhs2011
    , contributor
    Comments (21) | Send Message
     
    Krystexxa is a very good product but their marketing Team is bad.
    19 Mar 2013, 10:31 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs